The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...icines for all patients with MDR-TB.
more
This core package of materials provides a comprehensive introduction to the FAST strategy: a focused approach to stopping TB spread in congregate settings. This core package is composed of a booklet, job aids, posters, and a button which serves as a visual reminder to staff and patients of the impor...tance of this strategy in TB control. FAST can be implemented in both general and TB specific medical settings. Download the complete package from the website https://drtbnetwork.org/fast-tb-infection-control-strategy-core-package
more
This Rapid Communication aims to inform national TB programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.
Mid-term review of The National AIDS Programme 2011-15
October 2013
The Global Programme on Tuberculosis & Lung Health of the World Health Organization (WHO/GTB) is now combining all current recommendations into one overall set of consolidated guidelines on TB. The guidelines contain recommendations pertaining to all areas related to the programmatic management of T...B (e.g. screening, preventive treatment, diagnostics, patient support, and the treatment of drug-susceptible TB and DR-TB). The consolidated guidelines contain modules specific to each programmatic area.
more
Tuberculosis MDR-TB & XDR-TB The 2008 Report
Version 1.0, 2014-11-21
Introduction:
This document lists TB indicators that can be derived from the recording and reporting tools defined
in Definitions and reporting framework for tuberculosis – 2013 revision (WHO/HTM/TB/2013.2).
Geneva, World Health Organization; 2013. (http://www.who.int/t...b/publications/definitions/en/).
More details on the rationale, calculation and use of these indicators are available in the following
publications:
• Understanding and using tuberculosis data (WHO/HTM/TB/2014.09). Geneva, World Health
Organization. 2014.
(http://www.who.int/tb/publications/understanding_and_using_tb_data/en/)
• Companion handbook to the WHO guidelines for the programmatic management of drugresistant
tuberculosis (WHO/HTM/TB/2014.11). Geneva, World Health Organization. 2014.
(http://www.who.int/tb/publications/pmdt_companionhandbook/en/)
• A guide to monitoring and evaluation for collaborative TB/HIV activities: 2014 revision. Geneva,
World Health Organization. 2014.
more
Death investigation sheet concerning tuberculosis: Other Health Units and with family members
Características farmacológicas y clínicas más relevantes de los Medicamentos Esenciales utilizados en el manejo de las enfermedades infecciosas prevalentes en el primer nivel de atención. La misma se agrupa a su vez en: antibióticos, antimicóticos, antivirales, antiparasitarios y fármacos pa...ra el tratamiento de la Tuberculosis
more